NASDAQ:ADXN Addex Therapeutics (ADXN) Stock Price, News & Analysis → Thousands of investors use this no cost solution | Do you? (From Insider Financial) (Ad) Free ADXN Stock Alerts $15.55 -3.19 (-17.02%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$15.09▼$16.8950-Day Range$8.96▼$27.9052-Week Range$5.00▼$27.90Volume11,507 shsAverage Volume16,868 shsMarket Capitalization$16.48 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Addex Therapeutics alerts: Email Address Addex Therapeutics MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.85% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.39Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($17.20) to ($11.80) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.73 out of 5 starsMedical Sector829th out of 907 stocksPharmaceutical Preparations Industry391st out of 421 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Addex Therapeutics. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.85% of the float of Addex Therapeutics has been sold short.Short Interest Ratio / Days to CoverAddex Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Addex Therapeutics has recently decreased by 26.89%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAddex Therapeutics does not currently pay a dividend.Dividend GrowthAddex Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ADXN. Previous Next 2.4 News and Social Media Coverage News SentimentAddex Therapeutics has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Addex Therapeutics this week, compared to 0 articles on an average week.Search Interest2 people have searched for ADXN on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Addex Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Addex Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders15.00% of the stock of Addex Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 16.14% of the stock of Addex Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Addex Therapeutics are expected to grow in the coming year, from ($17.20) to ($11.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Addex Therapeutics is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Addex Therapeutics is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAddex Therapeutics has a P/B Ratio of 12.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Insider FinancialThousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.Simply tap here now to subscribe and start getting "Insider Financial Advantage" About Addex Therapeutics Stock (NASDAQ:ADXN)Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for pain, anxiety, and addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.Read More ADXN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADXN Stock News HeadlinesApril 19, 2024 | globenewswire.comAddex to Present at the Swiss Biotech Day 2024April 18, 2024 | investorplace.comADXN Stock Earnings: Addex Therapeutics Reported Results for Q4 2023April 25, 2024 | Insider Financial (Ad)Thousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.April 18, 2024 | seekingalpha.comAddex Therapeutics GAAP EPS of -CHF 0.14, revenue of CHF 1.65MApril 18, 2024 | globenewswire.comAddex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate UpdateApril 11, 2024 | globenewswire.comAddex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024April 3, 2024 | finanznachrichten.deNeurosterix launches with $63M to Advance Allosteric Modulator Therapeutics for Neurological DisordersApril 3, 2024 | markets.businessinsider.comAddex Announces Launch Of Neurosterix In Partnership With Perceptive - Quick FactsApril 25, 2024 | Insider Financial (Ad)Thousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.April 3, 2024 | globenewswire.comAddex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological DisordersMarch 14, 2024 | globenewswire.comAddex to Present at the Bio-Europe Spring 2024 ConferenceFebruary 22, 2024 | benzinga.comAddex Therapeutics Stock (NASDAQ:ADXN), Short Interest ReportJanuary 31, 2024 | finance.yahoo.comAddex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.January 9, 2024 | finance.yahoo.comAddex to Present at the Swiss Equities Baader ConferenceJanuary 5, 2024 | finance.yahoo.comAddex to Present at Biotech Showcase™ 2024December 23, 2023 | thestreet.comAddex Therapeutics LtdDecember 20, 2023 | finanznachrichten.deAddex Therapeutics: Addex Shareholders Approve All Resolutions at Extraordinary General MeetingDecember 20, 2023 | finance.yahoo.comAddex Shareholders Approve All Resolutions at Extraordinary General MeetingDecember 14, 2023 | finance.yahoo.comAddex Creates Treasury SharesNovember 29, 2023 | msn.comAddex Therapeutics GAAP EPS of -CHF0.03, income of CHF0.33MNovember 29, 2023 | markets.businessinsider.comAddex Therapeutics Posts Narrower Loss In Q3 - Quick FactsNovember 29, 2023 | finance.yahoo.comAddex Reports Q3 2023 Financial Results and Provides Corporate UpdateNovember 28, 2023 | finance.yahoo.comAddex Convenes Extraordinary General MeetingNovember 23, 2023 | finance.yahoo.comAddex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on November 29, 2023November 14, 2023 | finance.yahoo.comAddex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of PatientsNovember 2, 2023 | finance.yahoo.comAddex Announces Participation in the Bio-Europe 2023 ConferenceOctober 21, 2023 | finanznachrichten.deAddex Therapeutics: Addex Completes ADS Ratio ChangeSee More Headlines Receive ADXN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Addex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today4/24/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ADXN CUSIPN/A CIK1574232 Webwww.addextherapeutics.com Phone011-41-22-884-1555Fax41-22-884-1556Employees24Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($19.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,760,000.00 Net Margins-653.33% Pretax Margin-654.37% Return on Equity-277.44% Return on Assets-156.74% Debt Debt-to-Equity RatioN/A Current Ratio1.46 Quick Ratio1.46 Sales & Book Value Annual Sales$1.80 million Price / Sales9.16 Cash FlowN/A Price / Cash FlowN/A Book Value$1.20 per share Price / Book12.96Miscellaneous Outstanding Shares1,060,000Free Float901,000Market Cap$16.48 million OptionableNot Optionable Beta1.66 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Timothy Mark Dyer (Age 56)Co-Founder, CEO & Director Dr. Roger G. Mills M.D. (Age 67)Chief Medical Officer & Director Mr. Lénaic Teyssédou (Age 38)Head of Finance Dr. Jean-Philippe Rocher Ph.D. (Age 65)Head of Discovery - Chemistry Dr. Robert Lutjens (Age 56)Head of Discovery - Biology Dr. Mikhail Kalinichev Ph.D. (Age 57)Head of Translational Science More ExecutivesKey CompetitorsAptorum GroupNASDAQ:APMBioVieNASDAQ:BIVIRenovoRxNASDAQ:RNXTVincerx PharmaNASDAQ:VINCAlaunos TherapeuticsNASDAQ:TCRTView All CompetitorsInstitutional OwnershipArmistice Capital LLCSold 494,000 shares on 2/13/2024Ownership: 4.343%View All Institutional Transactions ADXN Stock Analysis - Frequently Asked Questions Should I buy or sell Addex Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Addex Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ADXN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADXN, but not buy additional shares or sell existing shares. View ADXN analyst ratings or view top-rated stocks. How have ADXN shares performed in 2024? Addex Therapeutics' stock was trading at $6.05 at the beginning of 2024. Since then, ADXN shares have increased by 157.0% and is now trading at $15.55. View the best growth stocks for 2024 here. Are investors shorting Addex Therapeutics? Addex Therapeutics saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 8,700 shares, a decline of 26.9% from the March 15th total of 11,900 shares. Based on an average trading volume of 17,000 shares, the days-to-cover ratio is presently 0.5 days. Approximately 0.9% of the company's stock are short sold. View Addex Therapeutics' Short Interest. When is Addex Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ADXN earnings forecast. How were Addex Therapeutics' earnings last quarter? Addex Therapeutics Ltd (NASDAQ:ADXN) posted its earnings results on Thursday, November, 4th. The company reported ($14.40) earnings per share for the quarter, hitting the consensus estimate of ($14.40). The firm had revenue of $0.83 million for the quarter, compared to analysts' expectations of $0.42 million. Addex Therapeutics had a negative net margin of 653.33% and a negative trailing twelve-month return on equity of 277.44%. During the same quarter in the previous year, the company earned ($15.60) EPS. When did Addex Therapeutics' stock split? Shares of Addex Therapeutics reverse split before market open on Monday, October 23rd 2023. The 1-20 reverse split was announced on Monday, October 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Addex Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Addex Therapeutics investors own include Achillion Pharmaceuticals (ACHN), ACADIA Pharmaceuticals (ACAD), Arbutus Biopharma (ABUS), Abacus Property Group (ABP), Advanced BioMedical Technologies (ABMT), Abiomed (ABMD), ARCA biopharma (ABIO), Abeona Therapeutics (ABEO) and Abcam (ABCZY). How do I buy shares of Addex Therapeutics? Shares of ADXN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ADXN) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersNew Trump BombshellThe Freeport Society1970’s computer coder issues shocking A.I. warningTradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Addex Therapeutics Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
